Mehdi Nikparvarfard, M.D.; Decision and Order, 14503-14504 [2018-06870]
Download as PDF
Federal Register / Vol. 83, No. 65 / Wednesday, April 4, 2018 / Notices
about the disposition of any firearm in
the course of a criminal investigation.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: An estimated 9,056
respondents will respond approximately
1,269.59375 times, and it will take each
respondent approximately 1.05 minutes
to complete each response.
6. An estimate of the total public
burden (in hours) associated with the
collection: The estimated annual public
burden associated with this collection is
201,205 hours which is equal to 9,056
(# of respondents) * 1,269.59375 (# of
responses per person) * .0175 (1.05
minutes).
7. An Explanation of the Change in
Estimates: The increase in total
responses by 6,678, total respondents by
1,523,647 and total burden hours by
23,673, are due to a general increase in
both the number of firearms
manufacturers that respond to this
collection and the number of firearms
produced each year.
If additional information is required
contact: Melody Braswell, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, 3E.405A,
Washington, DC 20530.
Dated: March 29, 2018.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2018–06768 Filed 4–3–18; 8:45 am]
BILLING CODE 4410–FY–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
amozie on DSK30RV082PROD with NOTICES
Mehdi Nikparvarfard, M.D.; Decision
and Order
On October 20, 2017, the Acting
Assistant Administrator, Diversion
Control Division, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause to Mehdi Nikparvarfard,
M.D. (Registrant), of Philadelphia,
Pennsylvania. The Show Cause Order
proposed the revocation of Registrant’s
Certificate of Registration No.
BN8871231 on the ground that he has
‘‘no state authority to handle controlled
substances.’’ Order to Show Cause,
Government Exhibit (GX) 2, at 1 (citing
21 U.S.C. 824(a)(3)). For the same
reason, the Order also proposed the
denial of any of Registrant’s
‘‘applications for renewal or
modification of such registration and
VerDate Sep<11>2014
18:12 Apr 03, 2018
Jkt 244001
any applications for any other DEA
registrations.’’ Id.
With respect to the Agency’s
jurisdiction, the Show Cause Order
alleged that Registrant is registered as a
practitioner in schedules II through V,
pursuant to DEA Certificate of
Registration No. BN8871231, at the
address of Advanced Urgent Care, 5058
City Ave., Philadelphia, Pennsylvania.
Id. The Order also alleged that this
registration does not expire until
October 31, 2019. Id.
As substantive grounds for the
proceeding, the Show Cause Order
alleged that on September 15, 2017, the
Commonwealth of Pennsylvania State
Board of Medicine ‘‘issued an Order of
Temporary Suspension and Notice of
Hearing in which it suspended
[Registrant’s] license to practice’’
medicine. Id. The Order alleged that, as
a result, he is ‘‘currently without
authority to practice medicine or handle
controlled substances in the
Commonwealth of Pennsylvania, the
[S]tate in which [he is] registered with
the DEA.’’ Id. at 1–2. Based on his ‘‘lack
of authority to handle controlled
substances in the Commonwealth of
Pennsylvania,’’ the Order asserted that
‘‘DEA must revoke’’ his registration. Id.
at 2 (citing 21 U.S.C. 824(a)(3); 21 CFR
1301.37(b)).
The Show Cause Order notified
Registrant of his right to request a
hearing on the allegations or to submit
a written statement in lieu of a hearing,
the procedure for electing either option,
and the consequence for failing to elect
either option. Id. (citing 21 CFR
1301.43). The Show Cause Order also
notified Registrant of his right to submit
a corrective action plan. Id. at 2–3
(citing 21 U.S.C. 824(c)(2)(C)).
The Government states that on
October 27, 2017, ‘‘personnel from
DEA’s Philadelphia Field Division
personally served the [Show Cause]
Order on Registrant at the Philadelphia
Federal Detention Center where he was
incarcerated.’’ Government’s Request for
Final Agency Action (RFFA), at 2 (citing
GX 5). Specifically, a DEA Diversion
Investigator from that Field Division
states that she, along with a Task Force
Officer, ‘‘presented the [Order] to Dr.
Nikparvar-Fard’’ and that he ‘‘took the
[Order].’’ GX5, at 1.
On December 21, 2018, the
Government forwarded its Request for
Final Agency Action and an evidentiary
record to my Office. Therein, the
Government represents that it has not
received a hearing request and that
Registrant ‘‘has not otherwise
corresponded or communicated with
DEA regarding the Order served on
him.’’ RFFA, at 2. Based on the
PO 00000
Frm 00094
Fmt 4703
Sfmt 4703
14503
Government’s representation and the
record, I find that more than 30 days
have passed since the Order to Show
Cause was served on Registrant, and he
has neither requested a hearing nor
submitted a written statement in lieu of
a hearing. See 21 CFR 1301.43(d).
Accordingly, I find that Registrant has
waived his right to a hearing or to
submit a written statement and issue
this Decision and Order based on
relevant evidence submitted by the
Government. I make the following
findings.
Findings of Fact
Registrant is a physician who is
registered as a practitioner in schedules
II–V pursuant to Certificate of
Registration No. BN8871231, at the
registered address of Advanced Urgent
Care, 5058 City Ave., Philadelphia,
Pennsylvania. See GX 1 (DEA
Certification of Registration Status), at 1.
Although not alleged in the Show Cause
Order, I also find that Registrant is the
holder of DATA-Waiver Identification
Number XN8871231, see id. at 1–2,1
which authorizes Registrant to dispense
or prescribe schedule III–V narcotic
controlled substances which ‘‘have been
approved by the Food and Drug
Administration . . . specifically for use
in maintenance or detoxification
treatment’’ for up to 275 patients. 21
CFR 1301.28(a) & (b)(1)(iii). His
registration does not expire until
October 31, 2019. Id.
The record also shows, and I so find,
that on September 22, 2016, Registrant
‘‘submitted a new online application for
a DEA registration bearing an address of
721 Bethleh[e]m Pike,
Montgomeryville,’’ Pennsylvania, as a
practitioner in schedules II–V. I find
that this new application remains
pending. See id. at 2.
On September 15, 2017, the
Commonwealth of Pennsylvania’s State
Board of Medicine issued an ‘‘Order of
Temporary Suspension and Notice
Hearing’’ to Registrant that
‘‘TEMPORARILY SUSPENDED’’ his
‘‘license to practice as a medical
1 The DEA Certification of Registration Status
confirms that Registrant has DATA-Waiver
Authority, but it does not include the identification
number for that authority. However, I take official
notice that the Agency’s registration records show
that Registrant’s DATA-Waiver Identification
Number is XN8871231. Under the Administrative
Procedure Act (APA), an agency ‘‘may take official
notice of facts at any stage in a proceeding—even
in the final decision.’’ U.S. Dept. of Justice,
Attorney General’s Manual on the Administrative
Procedure Act 80 (1947) (Wm. W. Gaunt & Sons,
Inc., Reprint 1979). In accordance with the APA
and DEA’s regulations, Registrant is ‘‘entitled on
timely request to an opportunity to show to the
contrary.’’ 5 U.S.C. 556(e); see also 21 CFR
1316.59(e).
E:\FR\FM\04APN1.SGM
04APN1
14504
Federal Register / Vol. 83, No. 65 / Wednesday, April 4, 2018 / Notices
amozie on DSK30RV082PROD with NOTICES
physician and surgeon’’ in
Pennsylvania. GX 3, at 1, 2. The Board
also directed Registrant to ‘‘surrender
his wall certificate(s), biennial renewal
certificate(s) and wallet card(s)’’ to state
authorities upon service of the Order.
Id. at 2. On October 6, 2017, the Board
issued an ‘‘Order Granting Continuance
and Continuing Suspension’’ stating
that Registrant had ‘‘agree[d] to toll the
180-day limit for the immediate and
temporary suspension of [his] license
. . . and [his] license shall remain
SUSPENDED until a preliminary
hearing is rescheduled or upon further
order of the State Board of Medicine.’’
GX 4, at 1. In light of the passage of time
since the effective date of the Order, I
have queried the Pennsylvania Medical
Board’s website regarding the status of
Registrant’s medical license, and I take
official notice 2 that Registrant’s
Pennsylvania medical license remains
suspended as of the date of this
decision. Based on the above, I find that
Registrant does not currently have
authority under the laws of
Pennsylvania to dispense controlled
substances.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823 of Title 21, ‘‘upon a
finding that the registrant . . . has had
his State license . . . suspended [or]
revoked . . . by competent State
authority and is no longer authorized by
State law to engage in the . . .
dispensing of controlled substances.’’
With respect to a practitioner, DEA has
long held that the possession of
authority to dispense controlled
substances under the laws of the State
in which a practitioner engages in
professional practice is a fundamental
condition for obtaining and maintaining
a registration. See, e.g., James L. Hooper,
76 FR 71371 (2011), pet. for rev. denied,
481 Fed. Appx. 826 (4th Cir. 2012); see
also Frederick Marsh Blanton, 43 FR
27616 (1978) (‘‘State authorization to
dispense or otherwise handle controlled
substances is a prerequisite to the
issuance and maintenance of a Federal
controlled substances registration.’’).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined ‘‘the term ‘practitioner’ [to]
mean[] a . . . physician . . . or other
person licensed, registered or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . to distribute,
dispense, [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
2 See
supra footnote 1.
VerDate Sep<11>2014
18:12 Apr 03, 2018
Jkt 244001
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which [s]he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the Act,
DEA has held repeatedly that revocation
of a practitioner’s registration is the
appropriate sanction whenever he is no
longer authorized to dispense controlled
substances under the laws of the State
in which he engages in professional
practice. See, e.g., Calvin Ramsey, 76 FR
20034, 20036 (2011); Sheran Arden
Yeates, M.D., 71 FR 39130, 39131
(2006); Dominick A. Ricci, 58 FR 51104,
51105 (1993); Bobby Watts, 53 FR
11919, 11920 (1988); Blanton, 43 FR
27616 (1978).
Moreover, because ‘‘the controlling
question’’ in a proceeding brought
under 21 U.S.C. 824(a)(3) is whether the
holder of a DEA registration ‘‘is
currently authorized to handle
controlled substances in the [S]tate,’’
Hooper, 76 FR at 71371 (quoting Anne
Lazar Thorn, 62 FR 12847, 12848
(1997)), the Agency has also long held
that revocation is warranted even where
a practitioner has lost his state authority
by virtue of the State’s use of summary
process and the State has yet to provide
a hearing to challenge the suspension.
Bourne Pharmacy, 72 FR 18273, 18274
(2007); Wingfield Drugs, 52 FR 27070,
27071 (1987). Thus, it is of no
consequence that the Pennsylvania
Medical Board has suspended
Registrant’s state license and that
Registrant may prevail in a future state
hearing. What is consequential is the
fact that Registrant is not currently
authorized to dispense controlled
substances in Pennsylvania, the State in
which he is registered. I will therefore
revoke his DEA registration, deny any
pending application to modify his
registration, or any pending application
for any other registration in
Pennsylvania.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 823(f) and 824(a), as well
as 28 CFR 0.100(b), I order that DEA
Certificate of Registration No.
BN8871231 and DATA-Waiver
Identification Number XN8871231,
issued to Mehdi Nikparvarfard, M.D.,
be, and it hereby is, revoked. I further
order that any pending application of
Mehdi Nikparvarfard to renew or
modify the above registration, or any
PO 00000
Frm 00095
Fmt 4703
Sfmt 4703
pending application for any other
registration in the Commonwealth of
Pennsylvania, be, and it hereby is,
denied. This Order is effective
immediately.3
Dated: March 26, 2018.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2018–06870 Filed 4–3–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Catalent Pharma
Solutions, LLC
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before May 4, 2018. Such persons
may also file a written request for a
hearing on the application on or before
May 4, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/LJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
DATES:
3 For the same reasons that led the Pennsylvania
Board of Medicine to suspend Registrant’s license,
I find that the public interest necessitates that this
Order be effective immediately. 21 CFR 1316.67.
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 83, Number 65 (Wednesday, April 4, 2018)]
[Notices]
[Pages 14503-14504]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-06870]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Mehdi Nikparvarfard, M.D.; Decision and Order
On October 20, 2017, the Acting Assistant Administrator, Diversion
Control Division, Drug Enforcement Administration (DEA), issued an
Order to Show Cause to Mehdi Nikparvarfard, M.D. (Registrant), of
Philadelphia, Pennsylvania. The Show Cause Order proposed the
revocation of Registrant's Certificate of Registration No. BN8871231 on
the ground that he has ``no state authority to handle controlled
substances.'' Order to Show Cause, Government Exhibit (GX) 2, at 1
(citing 21 U.S.C. 824(a)(3)). For the same reason, the Order also
proposed the denial of any of Registrant's ``applications for renewal
or modification of such registration and any applications for any other
DEA registrations.'' Id.
With respect to the Agency's jurisdiction, the Show Cause Order
alleged that Registrant is registered as a practitioner in schedules II
through V, pursuant to DEA Certificate of Registration No. BN8871231,
at the address of Advanced Urgent Care, 5058 City Ave., Philadelphia,
Pennsylvania. Id. The Order also alleged that this registration does
not expire until October 31, 2019. Id.
As substantive grounds for the proceeding, the Show Cause Order
alleged that on September 15, 2017, the Commonwealth of Pennsylvania
State Board of Medicine ``issued an Order of Temporary Suspension and
Notice of Hearing in which it suspended [Registrant's] license to
practice'' medicine. Id. The Order alleged that, as a result, he is
``currently without authority to practice medicine or handle controlled
substances in the Commonwealth of Pennsylvania, the [S]tate in which
[he is] registered with the DEA.'' Id. at 1-2. Based on his ``lack of
authority to handle controlled substances in the Commonwealth of
Pennsylvania,'' the Order asserted that ``DEA must revoke'' his
registration. Id. at 2 (citing 21 U.S.C. 824(a)(3); 21 CFR 1301.37(b)).
The Show Cause Order notified Registrant of his right to request a
hearing on the allegations or to submit a written statement in lieu of
a hearing, the procedure for electing either option, and the
consequence for failing to elect either option. Id. (citing 21 CFR
1301.43). The Show Cause Order also notified Registrant of his right to
submit a corrective action plan. Id. at 2-3 (citing 21 U.S.C.
824(c)(2)(C)).
The Government states that on October 27, 2017, ``personnel from
DEA's Philadelphia Field Division personally served the [Show Cause]
Order on Registrant at the Philadelphia Federal Detention Center where
he was incarcerated.'' Government's Request for Final Agency Action
(RFFA), at 2 (citing GX 5). Specifically, a DEA Diversion Investigator
from that Field Division states that she, along with a Task Force
Officer, ``presented the [Order] to Dr. Nikparvar-Fard'' and that he
``took the [Order].'' GX5, at 1.
On December 21, 2018, the Government forwarded its Request for
Final Agency Action and an evidentiary record to my Office. Therein,
the Government represents that it has not received a hearing request
and that Registrant ``has not otherwise corresponded or communicated
with DEA regarding the Order served on him.'' RFFA, at 2. Based on the
Government's representation and the record, I find that more than 30
days have passed since the Order to Show Cause was served on
Registrant, and he has neither requested a hearing nor submitted a
written statement in lieu of a hearing. See 21 CFR 1301.43(d).
Accordingly, I find that Registrant has waived his right to a hearing
or to submit a written statement and issue this Decision and Order
based on relevant evidence submitted by the Government. I make the
following findings.
Findings of Fact
Registrant is a physician who is registered as a practitioner in
schedules II-V pursuant to Certificate of Registration No. BN8871231,
at the registered address of Advanced Urgent Care, 5058 City Ave.,
Philadelphia, Pennsylvania. See GX 1 (DEA Certification of Registration
Status), at 1. Although not alleged in the Show Cause Order, I also
find that Registrant is the holder of DATA-Waiver Identification Number
XN8871231, see id. at 1-2,\1\ which authorizes Registrant to dispense
or prescribe schedule III-V narcotic controlled substances which ``have
been approved by the Food and Drug Administration . . . specifically
for use in maintenance or detoxification treatment'' for up to 275
patients. 21 CFR 1301.28(a) & (b)(1)(iii). His registration does not
expire until October 31, 2019. Id.
---------------------------------------------------------------------------
\1\ The DEA Certification of Registration Status confirms that
Registrant has DATA-Waiver Authority, but it does not include the
identification number for that authority. However, I take official
notice that the Agency's registration records show that Registrant's
DATA-Waiver Identification Number is XN8871231. Under the
Administrative Procedure Act (APA), an agency ``may take official
notice of facts at any stage in a proceeding--even in the final
decision.'' U.S. Dept. of Justice, Attorney General's Manual on the
Administrative Procedure Act 80 (1947) (Wm. W. Gaunt & Sons, Inc.,
Reprint 1979). In accordance with the APA and DEA's regulations,
Registrant is ``entitled on timely request to an opportunity to show
to the contrary.'' 5 U.S.C. 556(e); see also 21 CFR 1316.59(e).
---------------------------------------------------------------------------
The record also shows, and I so find, that on September 22, 2016,
Registrant ``submitted a new online application for a DEA registration
bearing an address of 721 Bethleh[e]m Pike, Montgomeryville,''
Pennsylvania, as a practitioner in schedules II-V. I find that this new
application remains pending. See id. at 2.
On September 15, 2017, the Commonwealth of Pennsylvania's State
Board of Medicine issued an ``Order of Temporary Suspension and Notice
Hearing'' to Registrant that ``TEMPORARILY SUSPENDED'' his ``license to
practice as a medical
[[Page 14504]]
physician and surgeon'' in Pennsylvania. GX 3, at 1, 2. The Board also
directed Registrant to ``surrender his wall certificate(s), biennial
renewal certificate(s) and wallet card(s)'' to state authorities upon
service of the Order. Id. at 2. On October 6, 2017, the Board issued an
``Order Granting Continuance and Continuing Suspension'' stating that
Registrant had ``agree[d] to toll the 180-day limit for the immediate
and temporary suspension of [his] license . . . and [his] license shall
remain SUSPENDED until a preliminary hearing is rescheduled or upon
further order of the State Board of Medicine.'' GX 4, at 1. In light of
the passage of time since the effective date of the Order, I have
queried the Pennsylvania Medical Board's website regarding the status
of Registrant's medical license, and I take official notice \2\ that
Registrant's Pennsylvania medical license remains suspended as of the
date of this decision. Based on the above, I find that Registrant does
not currently have authority under the laws of Pennsylvania to dispense
controlled substances.
---------------------------------------------------------------------------
\2\ See supra footnote 1.
---------------------------------------------------------------------------
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823 of Title
21, ``upon a finding that the registrant . . . has had his State
license . . . suspended [or] revoked . . . by competent State authority
and is no longer authorized by State law to engage in the . . .
dispensing of controlled substances.'' With respect to a practitioner,
DEA has long held that the possession of authority to dispense
controlled substances under the laws of the State in which a
practitioner engages in professional practice is a fundamental
condition for obtaining and maintaining a registration. See, e.g.,
James L. Hooper, 76 FR 71371 (2011), pet. for rev. denied, 481 Fed.
Appx. 826 (4th Cir. 2012); see also Frederick Marsh Blanton, 43 FR
27616 (1978) (``State authorization to dispense or otherwise handle
controlled substances is a prerequisite to the issuance and maintenance
of a Federal controlled substances registration.'').
This rule derives from the text of two provisions of the CSA.
First, Congress defined ``the term `practitioner' [to] mean[] a . . .
physician . . . or other person licensed, registered or otherwise
permitted, by . . . the jurisdiction in which he practices . . . to
distribute, dispense, [or] administer . . . a controlled substance in
the course of professional practice.'' 21 U.S.C. 802(21). Second, in
setting the requirements for obtaining a practitioner's registration,
Congress directed that ``[t]he Attorney General shall register
practitioners . . . if the applicant is authorized to dispense . . .
controlled substances under the laws of the State in which [s]he
practices.'' 21 U.S.C. 823(f). Because Congress has clearly mandated
that a practitioner possess state authority in order to be deemed a
practitioner under the Act, DEA has held repeatedly that revocation of
a practitioner's registration is the appropriate sanction whenever he
is no longer authorized to dispense controlled substances under the
laws of the State in which he engages in professional practice. See,
e.g., Calvin Ramsey, 76 FR 20034, 20036 (2011); Sheran Arden Yeates,
M.D., 71 FR 39130, 39131 (2006); Dominick A. Ricci, 58 FR 51104, 51105
(1993); Bobby Watts, 53 FR 11919, 11920 (1988); Blanton, 43 FR 27616
(1978).
Moreover, because ``the controlling question'' in a proceeding
brought under 21 U.S.C. 824(a)(3) is whether the holder of a DEA
registration ``is currently authorized to handle controlled substances
in the [S]tate,'' Hooper, 76 FR at 71371 (quoting Anne Lazar Thorn, 62
FR 12847, 12848 (1997)), the Agency has also long held that revocation
is warranted even where a practitioner has lost his state authority by
virtue of the State's use of summary process and the State has yet to
provide a hearing to challenge the suspension. Bourne Pharmacy, 72 FR
18273, 18274 (2007); Wingfield Drugs, 52 FR 27070, 27071 (1987). Thus,
it is of no consequence that the Pennsylvania Medical Board has
suspended Registrant's state license and that Registrant may prevail in
a future state hearing. What is consequential is the fact that
Registrant is not currently authorized to dispense controlled
substances in Pennsylvania, the State in which he is registered. I will
therefore revoke his DEA registration, deny any pending application to
modify his registration, or any pending application for any other
registration in Pennsylvania.
Order
Pursuant to the authority vested in me by 21 U.S.C. 823(f) and
824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of
Registration No. BN8871231 and DATA-Waiver Identification Number
XN8871231, issued to Mehdi Nikparvarfard, M.D., be, and it hereby is,
revoked. I further order that any pending application of Mehdi
Nikparvarfard to renew or modify the above registration, or any pending
application for any other registration in the Commonwealth of
Pennsylvania, be, and it hereby is, denied. This Order is effective
immediately.\3\
---------------------------------------------------------------------------
\3\ For the same reasons that led the Pennsylvania Board of
Medicine to suspend Registrant's license, I find that the public
interest necessitates that this Order be effective immediately. 21
CFR 1316.67.
Dated: March 26, 2018.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2018-06870 Filed 4-3-18; 8:45 am]
BILLING CODE 4410-09-P